HomeTrialNCT05518149
🔬NCT05518149Phase 3ACTIVE NOT RECRUITING

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)

Study Summary

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor \[SSRI\] or serotonin and norepinephrine reuptake inhibitor \[SNRI\]) in all participants with major depressive disorder (MDD).

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment840 participants
Primary Completion
Lead SponsorJanssen Research & Development, LLC
Data Retrieved2026-04-11 02:55:31.550417+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.